Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
NCT ID: NCT06446661
Last Updated: 2025-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
38 participants
INTERVENTIONAL
2025-12-15
2028-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High Intensity
Receives high-intensity text messaging for 2 cycles of treatment
High Intensity
Daily texts
Low Intensity
Receives no texts for 1st cycle and low-intensity texts for 2nd cycle
No Text Messagings
Standard Care
Low Intensity Text Messaging
Weekly Texts
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High Intensity
Daily texts
No Text Messagings
Standard Care
Low Intensity Text Messaging
Weekly Texts
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with ALL
* Currently receiving treatment with pediatric-based regimen that includes maintenance with mercaptopurine and methotrexate (e.g., CALGB 10403). Study participation begins with the start of maintenance, so enrollment occurs prior to the start of maintenance.
Exclusion Criteria
* Patient does not wish to participate
* Text messages will be crafted in the patient's preferred language for medical communication, so English fluency is not an enrollment requirement.
15 Years
39 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Chicago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wendy Stock
Role: PRINCIPAL_INVESTIGATOR
University of Chicago
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Clinical Trials Intake
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB23-1519
Identifier Type: -
Identifier Source: org_study_id